查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1482313

子宫颈癌诊断市场规模 - 按诊断测试、年龄层和最终用户 - 区域前景、竞争策略和细分市场预测（~2033 年）

Cervical Cancer Diagnostic Market Size- By Diagnostic Test, By Age Group, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 205 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计2033年，全球子宫颈癌诊断市场规模将成长至133.7亿美元，复合年增长率为5.28%。

2020年的COVID-19对市场产生了重大影响，子宫颈癌诊断市场也因医疗服务中断而面临挑战。由于注重 COVID-19 病例管理，子宫颈癌诊断数量减少，许多医疗机构推迟了非紧急手术和筛检，影响了接受常规筛检的女性数量。

本报告调查了全球子宫颈癌诊断市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测、各个细分市场/地区/主要国家的详细分析、竞争格局，我们编制了主要的概况主要企业。

目录

第一章简介

第二章调查方法

第三章执行摘要

第四章市场动态

  • 促进因素、抑制因素、机会与挑战分析
  • COVID-19 对市场的影响

第五章 市场变数与展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 热图分析

第六章 竞争状况

  • 製造地、销售区域、产品类型分布
  • 併购、联盟、产品发布、合作

第七章全球子宫颈癌诊断市场：依诊断测试

  • 全球市场规模、份额和预测
  • 子宫颈抹片检查
  • HPV检测
  • 切片检查/ECC
  • 阴道镜检查
  • 其他的

第八章全球子宫颈癌诊断市场：依年龄组别

  • 全球市场规模、份额和预测
  • 20-40岁
  • 40岁以上

第九章全球子宫颈癌诊断市场：依最终用户分类

  • 全球市场规模、份额和预测
  • 医院
  • 专科诊所
  • 癌症与放射治疗中心
  • 诊断中心
  • 其他的

第十章全球子宫颈癌诊断市场预测

  • 市场规模/市场占有率

第十一章全球子宫颈癌诊断市场：按地区

  • 市场规模/市场占有率趋势/预测
  • 亚太地区
  • 欧洲
  • 中东/非洲
  • 北美洲
  • 拉丁美洲

第十二章 公司简介

  • Zilico
  • Siemens Healthineers AG
  • QIAGEN NV
  • Abbott Laboratories
  • Becton, Dickinson and Co.
  • Quest Diagnostics Inc.
  • F. Hoffmann-La Roche Ltd.
  • Guided Therapeutics
  • Hologic Inc.
  • Bio-Rad Laboratories Inc.
  • 其他的

第十三章简称

第14章参考链接

第15章结论

第十六章 调查范围

简介目录
Product Code: HLCA2447

Cervical Cancer Diagnostic Market Introduction and Overview

According to SPER market research, 'Cervical Cancer Diagnostic Market Size- By Diagnostic Test, Age Group, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Cervical Cancer Diagnostic Market is predicted to reach 13.37 billion by 2033 with a CAGR of 5.28%.

Cervical cancer is a type of cancer that originates in the cervix. The thinner, lower end of the uterus is known as the cervix (womb). The uterus and vagina are connected via the cervix. Typically, it develops gradually over time. Dysplasia occurs in the cells of the cervix before cervical cancer develops. It begins to reveal aberrant cells in the cervical tissue. If the abnormal cells are not cleared or killed, they may eventually grow into malignant cells that proliferate and spread throughout the cervix and surrounding tissues.

The 2020 COVID-19 pandemic had a significant impact on the market. Cervical cancer diagnostics market faced challenges because to the COVID-19 pandemic-related disruptions in healthcare services. Cervical cancer diagnostics decreased as a result of the focus on COVID-19 case management. A significant number of healthcare facilities delayed non-urgent surgeries and screenings, which in turn affected the number of women receiving routine testing.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Diagnostic Test, By Age Group, By End User

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Zilico, Siemens Healthineers AG, QIAGEN NV, Abbott Laboratories, Becton, Dickinson and Co, Quest Diagnostics Inc, F. Hoffmann-La Roche Ltd, Guided Therapeutics, Hologic Inc, Bio-Rad Laboratories.

Global Cervical Cancer Diagnostic Market Segmentation:

By Diagnostic Test: Based on the Diagnostic Test, Global Cervical Cancer Diagnostic Market is segmented as, Pap Smear Tests, HPV Test, Biopsy and ECC, Colposcopy Tests, Others.

By End User: Based on the End User, Global Cervical Cancer Diagnostic Market is segmented as; Hospitals, Speciality Clinics, Cancer and Radiation Therapy Centers, Diagnostic Centers, Others.

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impacts of the Global Cervical Cancer Diagnostic Market.

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Cervical Cancer Diagnostic Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cervical Cancer Diagnostic Market

7. Global Cervical Cancer Diagnostic Market, By Diagnostic Test (USD Million) 2020-2033

  • 7.1. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Diagnostic Test, 2020-2026
  • 7.2. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Diagnostic Test, 2027-2033
  • 7.3. Pap Smear Tests
  • 7.4. HPV Test
  • 7.5. Biopsy and ECC
  • 7.6. Colposcopy Tests
  • 7.7. Others

8. Global Cervical Cancer Diagnostic Market, By Age Group (USD Million) 2020-2033

  • 8.1. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Age Group, 2020-2026
  • 8.2. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Age Group, 2027-2033
  • 8.3. 20 to 40 years
  • 8.4. above 40 years

9. Global Cervical Cancer Diagnostic Market, By End User (USD Million) 2020-2033

  • 9.1. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By End User, 2020-2026
  • 9.2. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By End User, 2027-2033
  • 9.3. Hospitals
  • 9.4. Specialty Clinics
  • 9.5. Cancer and Radiation Therapy Centers
  • 9.6. Diagnostic Centers
  • 9.7. Others

10. Global Cervical Cancer Diagnostic Market Forecast, 2020-2033 (USD Million)

  • 10.1. Global Cervical Cancer Diagnostic Market Size and Market Share

11. Global Cervical Cancer Diagnostic Market, By Region, 2020-2033 (USD Million)

  • 11.1. Global Cervical Cancer Diagnostic Market Size and Market Share By Region (2020-2026)
  • 11.2. Global Cervical Cancer Diagnostic Market Size and Market Share By Region (2027-2033)
  • 11.3. Asia-Pacific
    • 11.3.1. Australia
    • 11.3.2. China
    • 11.3.3. India
    • 11.3.4. Japan
    • 11.3.5. South Korea
    • 11.3.6. Rest of Asia-Pacific
  • 11.4. Europe
    • 11.4.1. France
    • 11.4.2. Germany
    • 11.4.3. Italy
    • 11.4.4. Spain
    • 11.4.5. United Kingdom
    • 11.4.6. Rest of Europe
  • 11.5. Middle East and Africa
    • 11.5.1. Kingdom of Saudi Arabia
    • 11.5.2. United Arab Emirates
    • 11.5.3. Qatar
    • 11.5.4. South Africa
    • 11.5.5. Egypt
    • 11.5.6. Morocco
    • 11.5.7. Nigeria
    • 11.5.8. Rest of Middle-East and Africa
  • 11.6. North America
    • 11.6.1. Canada
    • 11.6.2. Mexico
    • 11.6.3. United States
  • 11.7. Latin America
    • 11.7.1. Argentina
    • 11.7.2. Brazil
    • 11.7.3. Rest of Latin America

12. Company Profile

  • 12.1. Zilico
    • 12.1.1. Company details
    • 12.1.2. Financial outlook
    • 12.1.3. Product summary
    • 12.1.4. Recent developments
  • 12.2. Siemens Healthineers AG
    • 12.2.1. Company details
    • 12.2.2. Financial outlook
    • 12.2.3. Product summary
    • 12.2.4. Recent developments
  • 12.3. QIAGEN NV
    • 12.3.1. Company details
    • 12.3.2. Financial outlook
    • 12.3.3. Product summary
    • 12.3.4. Recent developments
  • 12.4. Abbott Laboratories
    • 12.4.1. Company details
    • 12.4.2. Financial outlook
    • 12.4.3. Product summary
    • 12.4.4. Recent developments
  • 12.5. Becton, Dickinson and Co.
    • 12.5.1. Company details
    • 12.5.2. Financial outlook
    • 12.5.3. Product summary
    • 12.5.4. Recent developments
  • 12.6. Quest Diagnostics Inc.
    • 12.6.1. Company details
    • 12.6.2. Financial outlook
    • 12.6.3. Product summary
    • 12.6.4. Recent developments
  • 12.7. F. Hoffmann-La Roche Ltd.
    • 12.7.1. Company details
    • 12.7.2. Financial outlook
    • 12.7.3. Product summary
    • 12.7.4. Recent developments
  • 12.8. Guided Therapeutics
    • 12.8.1. Company details
    • 12.8.2. Financial outlook
    • 12.8.3. Product summary
    • 12.8.4. Recent developments
  • 12.9. Hologic Inc.
    • 12.9.1. Company details
    • 12.9.2. Financial outlook
    • 12.9.3. Product summary
    • 12.9.4. Recent developments
  • 12.10. Bio-Rad Laboratories Inc.
    • 12.10.1. Company details
    • 12.10.2. Financial outlook
    • 12.10.3. Product summary
    • 12.10.4. Recent developments
  • 12.11. Others

13. List of Abbreviations

14. Reference Links

15. Conclusion

16. Research Scope